Alnylam Surpasses $1 Billion in Quarterly Revenue as AMVUTTRA Demand Surges (ALNY Q1 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Alnylam Pharmaceuticals achieved a historic milestone in the first quarter by surpassing $1 billion in quarterly product revenues for the first time, fueled by the explosive growth of its TTR franchise and the highly successful ongoing launch of AMVUTTRA.
Milestone $1 Billion Quarter Driven by TTR Franchise
Alnylam reported outstanding first-quarter financial results, achieving $1.036 billion in combined net product revenues, a 121% year-over-year increase. This historic milestone was primarily driven by the company's TTR franchise, which generated $910 million in net revenues, representing a 153% year-over-year surge and a 6% sequential increase from the fourth quarter. In the United States, TTR revenues grew an impressive 9% sequentially and more than 230% year-over-year, demonstrating robust patient demand for AMVUTTRA in ATTR cardiomyopathy. Meanwhile, the rare disease portfolio continued its steady performance, generating $126 million in net revenue, a 15% increase compared to the prior year.
Profitability Maintained Despite Expanding R&D Investments
The company achieved non-GAAP operating income of $339 million, a more than fourfold increase compared to the first quarter of the prior year, marking its third consecutive quarter of profitability on both a GAAP and non-GAAP basis. This strong bottom-line performance was achieved despite strategic increases in operating expenses. Non-GAAP research and development expenses rose 39% to $335 million to support three ongoing Phase III clinical studies, while non-GAAP selling, general, and administrative expenses increased 36% to $283 million to support global AMVUTTRA launch activities. Alnylam ended the quarter in a highly secure financial position with $3 billion in cash, cash equivalents, and marketable securities.
Clinical Success and Trial Expansions Bolster Next-Generation Pipeline
On the clinical front, Alnylam presented highly encouraging real-world data at the American College of Cardiology Annual Meeting, showing that greater than 93% of patients remained adherent to AMVUTTRA over an approximately four-year period. Building on this momentum, the company announced an expansion of its TRITON-CM Phase III cardiovascular outcomes trial for its next-generation TTR silencer, nucresiran. Taking advantage of faster-than-expected enrollment, Alnylam is exercising a prespecified protocol option to increase the trial size from 1,250 to approximately 1,750 patients. This strategic expansion is designed to further mitigate the risk of low event rates while maintaining the target for a potential launch by 2030.
Q&A Highlights First-Line AMVUTTRA Adoption and Competitive Dynamics
During the question-and-answer session, analysts focused on the dynamics of AMVUTTRA prescribing and the evolving competitive landscape. Chief Commercial Officer Tolga Tanguler explained that while new prescribers initially utilize AMVUTTRA equally across first- and second-line settings, growing physician experience consistently leads to deeper and sustained adoption in the first-line setting. Analysts also probed the potential impact of impending competitor data readouts and generic stabilizer entry. Executives expressed strong confidence that Alnylam's growth remains insulated from generic stabilizer pricing dynamics, emphasizing that AMVUTTRA's differentiated quarterly subcutaneous profile and high real-world adherence position the therapy as a foundational treatment regardless of changes in the stabilizer class.